Eton Pharmaceuticals announced FDA approval of KHINDIVI (hydrocortisone) oral solution, marking the first and only FDA-approved liquid hydrocortisone formulation for pediatric patients aged 5 and older with adrenocortical insufficiency.

Delta-Fly Pharma's DFP-14927, a drug delivery formulation of DFP-10917, is undergoing an expanded Phase I study in R/R colorectal cancer patients at MD Anderson and UCLA.

Recce Pharmaceuticals' R327G topical gel achieved a 93% primary efficacy endpoint in treating acute bacterial skin and skin structure infections (ABSSSI) and diabetic foot infections (DFI).

Ocugen has initiated a Phase 1 clinical trial for OCU200, a novel integrin-targeting biologic, in patients with diabetic macular edema (DME).

• Intas Pharmaceuticals has been granted permission by the CDSCO's Subject Expert Committee to proceed with a Phase III clinical trial for its R-hFSH solution for injection. • The trial will assess the safety, efficacy, and immunogenicity of Intas' R-hFSH compared to Merck Serono's Gonal-F in adult females undergoing assisted reproductive technology. • The CDSCO panel recommended including more tertiary care centers and government sites in the Phase III clinical trial to ensure a diverse study population. • R-hFSH, a recombinant human follicle-stimulating hormone, is crucial for ovarian follicular growth in women and spermatogenesis in men with specific hormonal deficiencies.

Jazz Pharmaceuticals presented updated Phase 2 data at ESMO 2024 for zanidatamab plus chemotherapy in HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA).

Rocket Pharmaceuticals has completed enrollment in its Phase 2 pivotal trial of RP-A501 for male patients with Danon disease.

Enanta Pharmaceuticals' EDP-323 demonstrated significant viral load reduction in a Phase 2a human challenge trial for Respiratory Syncytial Virus (RSV).

Alnylam Pharmaceuticals initiated a Phase 1 clinical trial for ALN-HTT02, a novel RNAi therapeutic targeting the huntingtin (HTT) gene for Huntington's disease (HD).

KP104, a dual-targeting complement inhibitor, demonstrates long-term safety and efficacy in complement inhibitor-naïve PNH patients.

Identiv and Novanta have formed a strategic partnership to develop integrated RFID solutions for medical device manufacturers, combining Identiv's RFID inlays with Novanta's ThingMagic reader technology.

Gujarat-based Senores Pharmaceuticals has strategically acquired 14 Abbreviated New Drug Applications from Dr. Reddy's Laboratories, with 13 already FDA-approved and one pending approval.

Processa Pharmaceuticals has dosed the first patient in a Phase II clinical trial of Next Generation Capecitabine (NGC-Cap) for advanced or metastatic breast cancer.

Marinus Pharmaceuticals' RAISE trial evaluated IV ganaxolone for refractory status epilepticus (RSE), meeting one co-primary endpoint.

Arrowhead Pharmaceuticals has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, marking the first investigational RNAi therapeutic to target a gene expressed in adipose tissue for obesity treatment.

Rhythm Pharmaceuticals' Imcivree (setmelanotide) demonstrated a 19.8% placebo-adjusted reduction in BMI over 52 weeks in patients with acquired hypothalamic obesity, a rare condition caused by hypothalamic damage.

Meitheal Pharmaceuticals has launched paclitaxel protein-bound particles for injectable suspension, a generic version of Abraxane, through an exclusive licensing agreement with parent company Hong Kong King-Friend Industry.

GSK has agreed to acquire efimosfermin alfa, a phase III-ready liver disease drug, from Boston Pharmaceuticals in a deal worth up to $2 billion.

Foresee Pharmaceuticals has terminated its Phase 2 trial of mirivadelgat for Fanconi anemia due to significant patient recruitment challenges and shifting research priorities in the field.

Rivus Pharmaceuticals' HU6 demonstrated statistically significant reductions in fat mass and visceral fat in obese patients with heart failure with preserved ejection fraction (HFpEF).